212 related articles for article (PubMed ID: 21262425)
1. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
Harenberg J
Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
[TBL] [Abstract][Full Text] [Related]
2. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
Harenberg J
Clin Appl Thromb Hemost; 2011; 17(6):E158-64. PubMed ID: 21406409
[TBL] [Abstract][Full Text] [Related]
3. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
4. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
5. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
Walenga JM; Jackson CM; Kessler CM
Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
[TBL] [Abstract][Full Text] [Related]
6. The United States Food and Drugs Administration approves a generic enoxaparin.
Ofosu FA
Clin Appl Thromb Hemost; 2011 Feb; 17(1):5-8. PubMed ID: 21159709
[TBL] [Abstract][Full Text] [Related]
7. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins.
Ofosu FA
Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312
[TBL] [Abstract][Full Text] [Related]
8. New and generic anticoagulants and biosimilars: safety considerations.
Kalodiki E; Fareed J
Clin Appl Thromb Hemost; 2011 Apr; 17(2):136-9. PubMed ID: 21159711
[TBL] [Abstract][Full Text] [Related]
9. Generic versus branded enoxaparin in the prevention of venous thromboembolism following major abdominal surgery: report of an exploratory clinical trial.
Gomes M; Ramacciotti E; Henriques AC; Araujo GR; Szultan LA; Miranda F; Thethi I
Clin Appl Thromb Hemost; 2011; 17(6):633-9. PubMed ID: 21949036
[TBL] [Abstract][Full Text] [Related]
10. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
[TBL] [Abstract][Full Text] [Related]
11. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States.
Caprini JA; Arcelus J; Sehgal LR; Cohen EB; Reyna JJ
Int Angiol; 2002 Mar; 21(1):78-85. PubMed ID: 11941278
[TBL] [Abstract][Full Text] [Related]
12. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
Haas S
Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparins in clinical practice.
Hunt D
South Med J; 1998 Jan; 91(1):2-10. PubMed ID: 9438394
[TBL] [Abstract][Full Text] [Related]
15. Ensuring safety of biosimilar low-molecular-weight heparins: a consensus statement of the International Union of Angiology .
Harenberg J; Kalodiki E; Walenga JM;
Int Angiol; 2012 Apr; 31(2):101-4. PubMed ID: 22466973
[No Abstract] [Full Text] [Related]
16. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients.
Deitelzweig SB; Vanscoy GJ; Niccolai CS; Rihn TL
Ann Pharmacother; 2003 Mar; 37(3):402-11. PubMed ID: 12639173
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
Nishioka J; Goodin S
J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
[TBL] [Abstract][Full Text] [Related]
18. Are the available low-molecular-weight heparin preparations the same?
Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight heparins in the outpatient management of venous thromboembolism.
Bick RL
Semin Thromb Hemost; 1999; 25 Suppl 3():97-9. PubMed ID: 10549723
[TBL] [Abstract][Full Text] [Related]
20. Recent clinical trials in the treatment of venous thromboembolism and unstable angina with low molecular weight heparins.
Hirsh J
Curr Opin Hematol; 1998 Sep; 5(5):360-5. PubMed ID: 9776217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
